Amneal Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Amneal Pharmaceuticals kazanç ve gelirin sırasıyla yıllık 19.9% ve 5% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 16.9% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 42% olacağı tahmin edilmektedir.

Anahtar bilgiler

19.9%

Kazanç büyüme oranı

16.90%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	11.2%
Gelir büyüme oranı	5.0%
Gelecekteki özkaynak getirisi	41.95%
Analist kapsamı	Low
Son güncelleme	04 Mar 2026

Gelecekteki son büyüme güncellemeleri

Recent updates

Amneal: Growing Drug Portfolio, Positive Cash Flow, Outweighing Leverage Risks

Dec 18

Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Nov 30

Amneal Pharmaceuticals' (NASDAQ:AMRX) Earnings May Just Be The Starting Point

Nov 14

Results: Amneal Pharmaceuticals, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Aug 08

Why Investors Shouldn't Be Surprised By Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Low P/S

Jul 24

Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price

Nov 10

Amneal Pharmaceuticals: Maintaining Momentum Is Key To Success

Jul 10

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:AMRX - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2028	3,505	N/A	555	435	2
12/31/2027	3,296	107	343	372	4
12/31/2026	3,090	82	333	383	4
12/31/2025	3,019	72	226	340	N/A
9/30/2025	2,935	6	237	328	N/A
6/30/2025	2,853	3	262	351	N/A
3/31/2025	2,830	-13	233	307	N/A
12/31/2024	2,794	-117	220	295	N/A
9/30/2024	2,680	-184	229	313	N/A
6/30/2024	2,598	-175	176	252	N/A
3/31/2024	2,495	-169	124	201	N/A
12/31/2023	2,394	-84	276	346	N/A
9/30/2023	2,386	10	137	186	N/A
6/30/2023	2,312	-2	114	199	N/A
3/31/2023	2,272	-135	-5	84	N/A
12/31/2022	2,212	-130	-25	65	N/A
9/30/2022	2,139	-132	53	152	N/A
6/30/2022	2,122	-134	80	140	N/A
3/31/2022	2,098	2	161	214	N/A
12/31/2021	2,094	11	189	242	N/A
9/30/2021	2,067	14	219	285	N/A
6/30/2021	2,058	9	176	247	N/A
3/31/2021	1,987	-17	408	478	N/A
12/31/2020	1,993	91	313	379	N/A
9/30/2020	1,880	62	183	222	N/A
6/30/2020	1,739	-194	283	317	N/A
3/31/2020	1,679	-199	71	159	N/A
12/31/2019	1,626	-362	-96	2	N/A
9/30/2019	1,727	-339	N/A	312	N/A
6/30/2019	1,825	-67	N/A	234	N/A
3/31/2019	1,834	-69	N/A	115	N/A
12/31/2018	1,663	-21	N/A	250	N/A
9/30/2018	1,459	155	N/A	56	N/A
6/30/2018	1,237	149	N/A	67	N/A
3/31/2018	1,083	168	N/A	192	N/A
12/31/2017	1,034	168	N/A	234	N/A
9/30/2017	1,039	54	N/A	205	N/A
12/31/2016	1,018	207	N/A	115	N/A
12/31/2015	866	169	N/A	105	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: AMRX 'nin tahmini kazanç büyümesi (yıllık 19.9% ) tasarruf oranının ( 3.4% ) üzerindedir.

Kazançlar ve Piyasa: AMRX şirketinin kazançlarının (yıllık 19.9% ) US pazarından (yıllık 15.7% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: AMRX şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: AMRX şirketinin gelirinin (yıllık 5% ) US pazarından (yıllık 10.4% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: AMRX şirketinin gelirinin (yıllık 5% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: AMRX 'nin Özsermaye Getirisi'nin 3 yıl içinde çok yüksek olması tahmin ediliyor ( 42 %).

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/03/11 15:18
Gün Sonu Hisse Fiyatı	2026/03/11 00:00
Kazançlar	2025/12/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, raporlarımızı nasıl kullanacağınız konusunda kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Amneal Pharmaceuticals, Inc. 19 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Glen Santangelo	Barclays
Gary Nachman	BMO Capital Markets Equity Research
David Buck	B. Riley Securities, Inc.

Amneal Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target increased by 7.9% to US$16.40

Amneal Pharmaceuticals, Inc. Provides Earnings Guidance for 2026

Price target increased by 8.6% to US$15.20

Price target increased by 8.0% to US$13.50

Amneal Pharmaceuticals, Inc. Updates Earnings Guidance for the Full Year 2025

Price target increased by 7.8% to US$12.67

Recent updates

Co-Founder exercised options and sold US$4.8m worth of stock

New major risk - Negative shareholders equity

Price target increased by 7.9% to US$16.40

Full year 2025 earnings: EPS exceeds analyst expectations

Amneal Pharmaceuticals, Inc. Provides Earnings Guidance for 2026

Price target increased by 8.6% to US$15.20

Amneal Pharmaceuticals, Inc. Announces Nationwide Opioids Settlement Agreement with Various States and Subdivisions

Amneal Pharmaceuticals, Inc. to Report Q4, 2025 Results on Feb 27, 2026

mAbxience and Amneal Pharmaceuticals, Inc. Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA

Amneal: Growing Drug Portfolio, Positive Cash Flow, Outweighing Leverage Risks

Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals

Amneal Pharmaceuticals, Inc. Announces Positive Interim Phase 4 Elevate-Pd Results with Crexont for Parkinson's Disease

Amneal Pharmaceuticals, Inc. Receives U.S. Fda Approval for Albuterol Sulfate Inhalation Aerosol

Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Independent Director recently sold US$586k worth of stock

Insider exercised options and sold US$1.2m worth of stock

Amneal Pharmaceuticals, Inc. Receives U.S. FDA Approval for Iohexol Injection

Amneal Pharmaceuticals' (NASDAQ:AMRX) Earnings May Just Be The Starting Point

Price target increased by 8.0% to US$13.50

Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Amneal Pharmaceuticals, Inc. Updates Earnings Guidance for the Full Year 2025

Amneal Pharmaceuticals, Inc. Launches Brekiya

Amneal Pharmaceuticals, Inc. to Report Q3, 2025 Results on Oct 30, 2025

Amneal Pharmaceuticals, Inc. Announces BLA Submission of Biosimilar Candidate to XOLAIR®? (Omalizumab)

Amneal Pharmaceuticals, Inc. Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%

Price target increased by 7.8% to US$12.67

Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution

Amneal Pharmaceuticals, Inc. Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension

Insider recently sold US$452k worth of stock

Insider notifies of intention to sell stock

Results: Amneal Pharmaceuticals, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Amneal Pharmaceuticals, Inc. Revises Earnings Guidance for the Year Ending December 31, 2025

Why Investors Shouldn't Be Surprised By Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Low P/S

Amneal Pharmaceuticals, Inc. to Report Q2, 2025 Results on Aug 05, 2025

Director recently sold US$453k worth of stock

Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension

Amneal Receives U.S. FDA Approval for Brekiya®? (Dihydroergotamine Mesylate) Injection for the Acute Treatment of Migraine and Cluster Headaches in Adults

Independent Director recently sold US$380k worth of stock

First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

Amneal Pharmaceuticals, Inc. Affirms Earnings Guidance for the Full Year 2025

Amneal Pharmaceuticals, Inc. to Report Q1, 2025 Results on May 02, 2025

Amneal Pharmaceuticals, Inc. Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with Crexont® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson's Disease

Amneal Pharmaceuticals, Inc. Announces Expanded Coverage for CREXONT®? (Carbidopa and Levodopa) to Enhance Access for Parkinson's Disease Patients in the U.S

Amneal Pharmaceuticals, Inc. and Shilpa Medicare Limited Launches BORUZU, First Ready-To-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma

Amneal Pharmaceuticals, Inc., Annual General Meeting, May 06, 2025

CREXONT And Metsera Partnerships Will Capitalize On Growing GLP-1 Market

Amneal Pharmaceuticals: Shares Still Feel Significantly Undervalued

Insider recently sold US$1.1m worth of stock

Co-Founder exercised options and sold US$2.9m worth of stock

Amneal’S Bla Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. Fda

New major risk - Revenue and earnings growth

Full year 2024 earnings: EPS misses analyst expectations

Amneal Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2025

Price target increased by 13% to US$11.25

Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide

There's No Escaping Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Muted Revenues

Amneal Pharmaceuticals, Inc. to Report Q4, 2024 Results on Feb 28, 2025

Amneal Pharmaceuticals, Inc. Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin

Independent Director recently sold US$334k worth of stock

Amneal Pharmaceuticals, Inc. Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist

Consensus EPS estimates fall by 17%

Senior VP recently sold US$376k worth of stock

Senior VP notifies of intention to sell stock

Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price

Third quarter 2024 earnings released: US$0.001 loss per share (vs US$0.063 profit in 3Q 2023)

Amneal Pharmaceuticals, Inc. Affirms Earnings Guidance for the Full Year 2024

New major risk - Shareholder dilution